Nevertheless, CRISPR/Cas9-mediated mutagenesis of the endogenous TCF7L2 binding site in intron 1 of LARGE2 reduced LARGE2 mRNA levels and the occurrence of high MW matriglycan on α-DG in CRC cells and PDTOs. The gene discussed is TCF7L2; the disease is colorectal carcinoma.